Study summary
An antibody-drug conjugate added to standard chemo keeps more people in remission at 5 years
64.9%progression-free at 5 years, vs 59.1% with R-CHOP
What was tested
Polatuzumab vedotin added to R-CHP chemotherapy (Pola-R-CHP), against standard R-CHOP, as first treatment for previously untreated DLBCL, followed over 5 years.
What they found
- 5-year progression-free survival was 64.9% vs 59.1%.
- The benefit was larger in higher-risk subgroups.
- Overall survival trended better but was not statistically significant.
What it means
Confirmed as a durable standard first treatment, not just a short-term gain.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.